Brandon Capital led cancer therapeutics startup Myricx Bio’s $8.5m seed round in 2019. Now Novartis is buying it for up to $2.16 billion. One of Australia’s longest tenured VC firms will soon enjoy its best ever return on a single investment following Novartis’ US$1.1 billion ($1.58 billion) acquisition of London biotech startup Myricx Bio. Melbourne-headquartered […]
These drugs work to treat diabetes and weight loss by suppressing the appetite and lowering blood sugar and A1C—which may end up being an effective treatment for Alzheimer’s, heart conditions, depression, and many other conditions.
The pharmaceutical company will pay an estimated $700 million to resolve an investigation by more than 40 states into the pharmaceutical firm’s marketing of its talcum powder, according to Bloomberg, following thousands of lawsuits alleging it failed to warn customers about cancer risks.